[Measurement of serum AMH levels in gynecology: indications and limits].
Antimüllerian hormone (AMH), a glycoprotein secreted by the granulosa cells of (pre)antral follicles, is a quantitative marker of the ovarian reserve. The dosage of AMH is predictive of the response to ovarian stimulation for in vitro fertilization and allows the detection of patients at risk of responding poorly to stimulation or of ovarian hyperstimulation syndrome (OHSS). AMH doesn't predict live-birth chances after IVF. Neither does AMH predict the chances of spontaneous pregnancy nor the success rates of ovarian stimulation with/without intra-uterine insemination. AMH is currently studied to predict the age at menopause, in the diagnosis of polycystic ovarian syndrome and in the context of surgical and medical treatments that can alter the ovarian reserve.
Département de Gynécologie et Obstétrique, HUG, Genève. isabelle.streuli@hcuge.ch
Isabelle
I
Streuli
Pablo
P
Cantero-Perez
Corinne
C
Miserez-Zaugg
D000375:Aging / Q000097:blood; D054304:Anti-Mullerian Hormone / Q000097:blood*; D015415:Biomarkers / Q000097:blood; D005260:Female; D005307:Fertilization in Vitro; D006801:Humans; D008593:Menopause / Q000097:blood; D010053:Ovary / Q000502:physiology; D011247:Pregnancy
D015415:Biomarkers; D054304:Anti-Mullerian Hormone